Back to companies

PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and markets medicines for the treatment of rare disorders. Its marketed products include Evrysdi (risdiplam) for spinal muscular atrophy, Translarna (ataluren) and Emflaza (deflazacort) for the treatment of Duchenne muscular dystrophy. The company's pipeline candidates target the treatment of Huntington’s disease; children with inherited mitochondrial disease; leiomyosarcoma; acute myelogenous leukemia; and aromatic L-amino acid decarboxylase deficiency. PTC Therapeutics works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. The company operates through its subsidiaries in the US and Europe. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

Headquarters United States of America

Address 100 Corporate Ct, South Plainfield, New Jersey, 07080-2400


Telephone 1 908 2227000

No of Employees 1,252

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange PTCT (NASD)

Revenue (2021) $538.6M 41.4% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX -19.6% (2021 vs 2020)

Market Cap* $2.6B

Net Profit Margin (2021) XXX 15.5% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

110+

Clinical Trials

Determine PTC Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Catalyst Calendar

Proactively evaluate PTC Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for PTC Therapeutics Inc’s relevant decision makers and contact details.

50+

Pipeline Drugs

Identify which of PTC Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

30+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

13+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

9

Sales & Consensus Forecasts

Understand the current and future drug revenue for PTC Therapeutics Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

4

Marketed Drugs

Understand PTC Therapeutics Inc’s commercialized product portfolio to stay one step ahead of the market.

1

Medical Marketed Products

A database of medical devices currently for sale around the world. Devices that have been approved by a regulatory authority are included.

1

Medical Clinical Trials

A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Translarna (Ataluren): Duchenne Muscular Dystrophy Evrysdi
Emflaza (Deflazacort): Duchenne Muscular Dystrophy Translarna
Tegsedi (Inotersen): Polyneuropathy Emflaza
XXX XXX
XXX XXX
XXX XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Regulatory Approval In May, the company announced that the U.S. Food and Drug Administration (FDA) approved a label extension for Evrysdi (risdiplam) to include infants under 2 months old with spinal muscular atrophy (SMA).
2022 Official Trials/Tests In March, the company announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD).
2022 Official Trials/Tests In March, the company initiated the PIVOT-HD Phase 2 clinical trial for evaluating PTC518 in patients with Huntington's disease.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters PTC Therapeutics Inc Astellas Pharma Inc Biogen Inc Daiichi Sankyo Co Ltd Nippon Shinyaku Co Ltd
Headquarters United States of America Japan United States of America Japan Japan
City South Plainfield Chuo-Ku Cambridge Chuo-Ku Kyoto-Shi
State/Province New Jersey Tokyo Massachusetts Tokyo Kyoto
No. of Employees 1,252 15,455 9,610 16,033 2,059
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Michael Schmertzler Chairman Executive Board 2004 70
Stuart W. Peltz, Ph.D. Director; Chief Executive Officer Executive Board 1998 62
Emily Hill Chief Financial Officer Senior Management 2019 42
Matthew B. Klein, M.D. Chief Operating Officer Senior Management 2022 50
Christine Utter Head - People Services; Chief Accounting Officer; Senior Vice President Senior Management 2019 44
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer